ClinicalTrials.gg
TerminatedNCT03549325Lac-3Updated Feb 12, 2026Results posted

A Study Assessing Colonisation & Immunogenicity After Nasal Inoculation With N. Lactamica and Eradication on Day 4 or 14

An interventional study of Neisseria lactamica in Meningitis, Meningococcal, sponsored by University Hospital Southampton NHS Foundation Trust. Terminated at 1 site in United Kingdom. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by University Hospital Southampton NHS Foundation Trust · Not applicable, Interventional, and Prevention

How we know

Why this study was terminated
Recruitment was paused in March 2020 due to the COVID pandemic. An interim data analysis was conducted in 2021 which confirmed that sufficient data had been collected to meet the primary objective, therefore the study was terminated.

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Mar 2017, registered Oct 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study is part of a project that aims to develop a vaccine with N. lactamica that prevents meningitis. The investigators have previously given nose drops containing N. lactamica to over 340 volunteers, and shown that many of the volunteers (35-60%) become colonised without causing any illness or disease. In the future the investigators would like to modify N. lactamica so that it can carry vaccine molecules into the nose of children. To do this the investigators need to know more about the immune response generated against N. lactamica. Previously the investigators have shown that inoculation resulted in an immune (antibody) response in volunteers who were colonised. Taking an antibiotic called ciprofloxacin will treat N.lactamica in the nose and throat of the volunteers. The investigators need to know if the immune response to N. lactamica is the same when colonised volunteers are treated with the antibiotic after 4 days, is the same if the investigators treat volunteers after 14 days of carriage. This information will inform future studies.

Read the detailed description

N. lactamica (Nlac) has been shown to be safe to use in human challenge experiments. Even at a very low dose of 10,000 colony forming units (cfu) long lasting colonisation with Nlac is easily induced in 35-65% of volunteers. The investigators have previously showed that increasing the inoculum to 100,000 cfu increased the subsequent carriage of Nlac to 50%. In 80-90% of those volunteers successfully colonised, this is detectable by 1-2 weeks.

Data regarding earlier detection of colonisation is currently lacking.

Colonisation has a clear effect on the volunteers nasal mucosal microbiome, in that meningococcal acquisition is effectively inhibited in volunteers who carry the organism. Colonisation is immunogenic, with an increase in specific serum IgG by 2 weeks and specific salivary IgA by 4 weeks.

No antibiotic eradication therapy has previously been given following experimental inoculation but Ciprofloxacin has been shown to be effective in the eradication of N. meningitidis.

To design future planned studies using Nlac nasal inoculation and colonisation in order to prevent invasive N. meningitidis disease, it is necessary to further evaluate the colonisation kinetics and efficacy of the eradication following antibiotic treatment. In previous challenges the investigators inoculated volunteers with Nlac and followed those volunteers for prolonged periods of time (over 6 months).

This study will compare the effect of short (4 days) versus longer (14 days) periods of nasal carriage of Nlac in volunteers on immunogenicity, and confirm the efficacy of antibiotic eradication therapy with ciprofloxacin.

Healthy adult volunteers will receive a nasal inoculation of Nlac with an antibiotic given on day 4 or 14. This information will be used to inform the design of future research into the colonisation and immunogenicity of related organisms.

Before designing future protocols the study investigators need to know whether a short containment of the volunteers will be sufficient for immunogenicity, and how quickly the volunteers can be discharged after antibiotic treatment.

A wild-type strain of Nlac (Y92-100) will be used for this study, selected because the investigators have previously used it safely in experimental challenge of over 340 human volunteers.

The same strain will be the parent strain for any future GMO work.

02

Conditions studied

  • Meningitis, Meningococcal

Keywords

  • Neisseria lactamica
  • healthy volunteers
  • nasal inoculation
  • colonisation
03

In context

Meningitis, Meningococcal

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

This study's enrollment of 21 is below the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.

Browse Meningitis, Meningococcal studies →

Lead sponsor

University Hospital Southampton NHS Foundation Trust is the lead sponsor of 150 studies on the registry; 35 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults aged 18 to 45 years inclusive on the day of enrolment
  • Fully conversant in the English language
  • Able and willing (in the investigator's opinion) to comply with all study requirements
  • Written to participate in the trial
  • Willingness to take an antibiotic regimen after inoculation according to the study protocol
  • For females only, willingness to practice continuous effective (see below) during the study and a negative pregnancy test on the day(s) of screening and inoculation

Exclusion criteria

Exclusion Criteria:

  • Current active smokers
  • N. lactamica or N. meningitidis detected on throat swab or nasal wash taken before the challenge
  • Individuals who have a current infection at the time of inoculation
  • Individuals who have been involved in other clinical trials involving receipt of an product over the last 12 weeks or if there is planned use of an investigational product during the study period
  • Individuals who have previously been involved in clinical trials investigating meningococcal vaccines or experimental challenge with N. lactamica
  • Use of systemic antibiotics within the period 30 days prior to the challenge
  • Any confirmed or suspected or immune-deficient state, including infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (topical are allowed)
  • Use of immunoglobulins or blood products within 3 months prior to enrolment.
  • History of allergic disease or reactions likely to be exacerbated by any component of the inoculum
  • to the use of ciprofloxacin, specifically a history of epilepsy, prolonged , to quinolones or a history of tendon disorders related to quinolone use
  • Any abnormal finding on clinical examination
  • Any other significant disease, disorder, or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data, for example recent surgery to the nasopharynx
  • Occupational, household or intimate contact with immunosuppressed persons
  • Pregnancy or lactation
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Group 1

    Nasal drops containing Neisseria lactamica are administered at Day 0 by the study doctor. Eradication therapy with the antibiotic Ciprofloxacin given on Day 4, unless required sooner. Follow up visits occur on Days 5, 14 and 32.

    Biological: Neisseria lactamica

  • Experimental
    Group 2

    Nasal drops containing Neisseria lactamica are administered at Day 0 by the study doctor. Follow up visits on Day 4 and 7 to check for N. lactamica carriage. Eradication therapy with the antibiotic Ciprofloxacin given on Day 14, unless required sooner. Follow up visits occur on Days 15, 24 and 42.

    Biological: Neisseria lactamica

Interventions

  • BiologicalNeisseria lactamica

    Colonisation by bacteria is an immunising event; we proved this in humans by inoculating university students intranasally with the harmless commensal N. lactamica and we observed both specific systemic and mucosal antibody responses by 4 weeks. Experimental challenge with defined bacteria could tease out the Th17-mediated response mechanisms, which include waning of immunity over time, the induction of an incorrectly polarised T cell response, lack of cross-reactivity between strains or active immune evasion mechanisms employed by bacteria to subvert host immune effector mechanisms.

06

What researchers measure

Primary outcomes

  1. Measure the Antibodies, by Serological Antibody Titration, of Short Term Colonisation and Longer Colonisation

    Measure any rise in serological specific antibodies from samples taken at the start of the study (Day 0) and samples taken on Day 14 post inoculation and Day 28 post antibiotic eradication (Group 1 = Day 32 or Group 2 = Day 42)

    Time frame: Up to 42 Days

Secondary outcomes

  1. Measure the Colonisation of Neisseria Lactamica

    Measure if Neisseria lactamica is able to colonise at or before Day 4 (for group 1) or Day 14 (for group 2) from cultured throat swabs.

    Time frame: Up to 14 Days

  2. Measure the Eradication of Neisseria Lactamica

    Record how successful eradication is up to Day 42, using throat swab samples.

    Time frame: Up to 42 Days

07

Results

Posted Feb 12, 2026

Participant flow

Healthy adult volunteers were recruited according to a REC approved recruitment strategy between 3/3/17 and 14/4/20. Participants attended a face to face screening visit at NIHR Southampton CRF to obtain informed consent and determine eligiblity

Participant flow — Overall Study
MilestoneGroup 1Group 2
Started138
Completed127
Not completed11
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryMeasure the Antibodies, by Serological Antibody Titration, of Short Term Colonisation and Longer Colonisation

Measure any rise in serological specific antibodies from samples taken at the start of the study (Day 0) and samples taken on Day 14 post inoculation and Day 28 post antibiotic eradication (Group 1 = Day 32 or Group 2 = Day 42)

Time frame:
Up to 42 Days
Reported as:
Median · Titres of antigen specific IgG
Measure the Antibodies, by Serological Antibody Titration, of Short Term Colonisation and Longer Colonisation
Titres of antigen specific IgGDay 0Day 14Eradication + 28
Nlac-IgG Group 15.3 (3.3 to 6.4)5.5 (3.9 to 6.6)5.6 (4.6 to 7.1)
Nlac-IgG Group 24.6 (3.2 to 9.5)13.4 (9.3 to 14.7)10.3 (7.7 to 13.1)
Nmen-IgG Group 122.6 (20.4 to 26.1)23.7 (18.5 to 27.8)23.2 (19.4 to 26.6)
Nmen-IgG Group 210.4 (8.0 to 13.9)17.3 (9.5 to 33.6)14.5 (9.5 to 22.3)
SecondaryMeasure the Colonisation of Neisseria Lactamica

Measure if Neisseria lactamica is able to colonise at or before Day 4 (for group 1) or Day 14 (for group 2) from cultured throat swabs.

Time frame:
Up to 14 Days
Reported as:
Count of participants · Participants
Measure the Colonisation of Neisseria Lactamica
ParticipantsGroup 1Group 2
Measure the Colonisation of Neisseria Lactamica76
SecondaryMeasure the Eradication of Neisseria Lactamica

Record how successful eradication is up to Day 42, using throat swab samples.

Time frame:
Up to 42 Days
Reported as:
Count of participants · Participants
Measure the Eradication of Neisseria Lactamica
ParticipantsGroup 1Group 2
Measure the Eradication of Neisseria Lactamica64

Adverse events

Collected over From enrolment until the end of follow up - 32 days post inoculation for Group 1 and 42 days post inoculation for Group 2. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 10/13 (0%)0/13 (0%)3/13 (23.1%)
Group 20/8 (0%)0/8 (0%)6/8 (75%)
Most frequent other events
Most frequent other events
EventGroup 1Group 2
Respiratory tract symptomsRespiratory, thoracic and mediastinal disorders3/132/8
Malaise / lethargy / headacheGeneral disorders0/132/8
Diarrhoea / vomitingGastrointestinal disorders0/131/8
Dysuria / cystitisRenal and urinary disorders0/131/8

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Group 1Group 2Total
Median33 (25 to 45)29 (25 to 39)31 (25 to 45)
Sex: Female, Male
Sex: Female, Male(Participants)Group 1Group 2Total
Female8816
Male505
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Group 1Group 2Total
Count of participants——0
Specific IgG titres
Specific IgG titres(Antibody titre)Group 1Group 2Total
Nlac-specific IgG titre5.3 (3.3 to 6.4)4.6 (3.2 to 9.5)5.0 (3.0 to 7.5)
Nmen-specific IgG titre22.6 (20.4 to 26.1)10.4 (8.0 to 13.9)17.1 (10.8 to 23.8)
08

Study locations

1 site
  • Southampton NIHR Clinical Research Facility
    Southampton, Hampshire SO166YD, United Kingdom
09

References and documents

Publications

  • Evans CM, Pratt CB, Matheson M, Vaughan TE, Findlow J, Borrow R, Gorringe AR, Read RC. Nasopharyngeal colonization by Neisseria lactamica and induction of protective immunity against Neisseria meningitidis. Clin Infect Dis. 2011 Jan 1;52(1):70-7. doi: 10.1093/cid/ciq065. PubMed 21148522 ↗
  • Dale AP, Theodosiou AA, Gbesemete DF, Guy JM, Jones EF, Hill AR, Ibrahim MM, de Graaf H, Ahmed M, Faust SN, Gorringe AR, Polak ME, Laver JR, Read RC. Effect of colonisation with Neisseria lactamica on cross-reactive anti-meningococcal B-cell responses: a randomised, controlled, human infection trial. Lancet Microbe. 2022 Dec;3(12):e931-e943. doi: 10.1016/S2666-5247(22)00283-X. PubMed 36462524 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Dec 2021, 56 months.

Results were first posted in Feb 2026, 4 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2017
First posted
Jun 8, 2018
StartActual
Mar 13, 2017
Primary completionActual
Dec 2, 2021
CompletionActual
Dec 2, 2021
Results first posted
Feb 12, 2026
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03549325
Responsible party
Sponsor
First posted
Jun 8, 2018
Start date
Mar 13, 2017
Primary completion
Dec 2, 2021
Completion
Dec 2, 2021
Results posted
Feb 12, 2026
Last update
Feb 12, 2026

Study contacts

Robert Read
principal investigator · University of Southampton

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion